TTrialPathMatch Me to Trials
← Back to trials
RecruitingGastric CancerGastroesophageal Junction CancerBiliary Tract Cancer

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Eligible age

18+ yrs

Accepts

All genders

Locations

5 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .

Sponsor: AstraZeneca

Where it's recruiting

California

Orange · Palo Alto · Santa Rosa

Kentucky

Louisville

New York

Commack

Rhode Island

Providence

Texas

Houston

Source: ClinicalTrials.gov · NCT06219941 · last updated 2026-09-30

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin · TrialPath